Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

By S. Whittaker, M. Demierre, Ellen J. Kim, A. Rook, A. Lerner, M. Duvic, J. Scarisbrick, S. Reddy, T. Robak, J. Becker and 3 more. Journal of Clinical Oncology, 2010

641 citations recorded by the source corpus.

Subfields: Dermatology, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/55cd7e391dcd18bb074238f217aad3c979fbb462

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Guangdi Wang
2. Tien L. Huang
3. Madhusoodanan Mottamal
4. Shilong Zheng

Citations in the corpus

• Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, methodology): “The second HDAC inhibitor approved for the treatment of CTCL was based on two large phase II studies: a multi-institutional study based at the NCI in the US (71 patients), and an international study (96 patients) [27,28].”
• Romidepsin in the treatment of cutaneous T-cell lymphoma (2011, neutral): “Nausea (all grades 52%–56%), asthenia (all grades 44%), anorexia (all grades 20%), vomiting (all grades 19%–26%), and aguesia (all grades 13%) were commonly seen in patients receiving romidepsin.(31,36) Most of these adverse events were mild (grade 1 or 2).”